Dublin, Aug. 29, 2019 (GLOBE NEWSWIRE) -- The "2nd Annual Next Gen Immuno-Oncology Congress" conference has been added to ResearchAndMarkets.com's offering.

The current revolution in immuno-oncology is being driven by Antibody Drug Conjugates, Immune Checkpoint Inhibitors, Bispecific Antibodies, and Cell Therapies.

Clinical trials have shown that cancer patients can tolerate this immune-based treatment more effectively than conventional treatments like chemotherapy and radiotherapy. It's clearly one of the hottest fields of Biopharma which has gained momentum in the past few years.

  • With more than 45 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in the development of ADC's, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, and Cellular Therapy.
  • Meet and network with experts from leading universities and industry sharing their knowledge on Preclinical and Translational Immuno-Oncology Developments, Next Gen CAR-T Cell Therapy, Immune Checkpoint Inhibitors, Monoclonal, and Bispecific Antibodies and more.
  • A platform to meet experts from Pharma, biopharma and biotech companies and increase your learning in Monoclonal and Bispecific Antibodies, Cell Therapy and Immune Checkpoint Inhibitors.

Key Highlights

  • Updates in development of monoclonal Abs and bispecific Abs
  • Immune Checkpoint Inhibitors and Combinations
  • Preclinical and Translational Immuno-Oncology Developments

Sessions

  • Targeted Antibodies and Combinations
  • Pre-clinical & Translational Immuno-Oncology Developments
  • New Antibody Formats
  • New Immune Checkpoints for Immunotherapy

Why Attend?

  • Find out new case studies of antibody projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you

Agenda

Day 1

Stream A: Monoclonal and Bispecific Antibodies

  • Opening remarks from the Chairman 09:00 - 09:05
  • Keynote: Learnings from the successful Cancer Immunotherapy Combinations and Bispecifics 09:05 - 09:35 Rakesh Dixit, CEO, Bionavigen
  • Natural single domain antibodies as potential alternatives to monoclonal antibodies in the next generation immunotherapy 09:35 - 10:05
    • Rajesh Singh, Laboratory Director, Abzyme Therapeutics
  • Morning Refreshments and Poster Presentations - One-to-One Networking Meetings 10:35 - 11:25
  • Novel conjugation technologies-Payload and Linkers 11:25 - 11:55
  • Improving recruitment of myeloid effector cells for antibody therapy 11:55 - 12:25
  • Therapeutic targeting of the tumor microenvironment 12:25 - 12:55
  • Lunch and Poster Presentations - One-to-One Networking Meetings 12:55 - 13:55
  • New Antibody Formats and Developments in CAR-T Cell Therapy
  • Biomarkers Associated with Clinical Outcomes in ZUMA-1 Supporting Approval of Yescarta 13:55 - 14:35
    • Vicki Plaks, Translational Lead, Principal Scientist, Translational Sciences, Kite Pharma
  • ex vivo PBMC Activation of Antitumor Activity Offers Accelerated Path to Clinical Application 14:35 - 15:05
    • Frank Borriello, CEO, Alloplex Biotherapeutics
  • Next-generation gene editing technology for allogeneic T cell therapeutics 15:05 - 15:35
    • Megan van Overbeek, Associate Director of Functional Genomics, Caribou Biosciences
  • Evening Refreshments and Poster Presentations - One-to-One Networking Meetings 16:05 - 16:55
  • Novel Bispecific PD-1 antibody therapeutic approach in solid tumours 16:55 - 17:25
  • Bicycle Drug Conjugate for treatment of solid tumours 17:25 - 17:55
  • Closing remarks from the Chairman 17:55 - 18:00
  • Cocktail Reception 18:00 - 19:00

Stream B: Immune Checkpoint Inhibitors & Combination Strategies

  • Opening remarks from the Chairman 09:00 - 09:05
  • Keynote 09:05 - 09:35
  • Breast Cancer Immunotherapy: Novel Combinations of Bria-IMT with Checkpoint Inhibitors 09:35 - 10:05
    • William Williams, President, CEO, BriaCell Corporation
  • Accelerating Therapeutic Antibody Discovery and Development with Innovative Humanized Mouse Models 10:05 - 11:25
    • Qingcong Lin, Senior Vice President, CEO, Biocytogen Boston Corporation
  • Pre-clinical & Translational Immuno-Oncology Developments
  • Reversing trastuzumab resistance in HER2+ breast cancer 11:25 - 11:55
    • RJ Tesi, CEO, CMO, INmune Bio Inc.
  • Creating novel hypotheses and evaluation in translational research 11:55 - 12:25
  • Humanized Mouse Models for Immuno-Oncology Research 12:25 - 13:55
    • Sebastien Tabruyn, Chief Scientific Officer, Transcure Bioservices
  • New Immune Checkpoints for Immunotherapy
  • Clinical development of GITR based immunotherapies 13:55 - 14:35
  • Girish Naik, Medical Director, Leap Therapeutics 14:35 - 15:05
  • Panel Discussion: Future of Biologics in Immune Checkpoint therapy 15:05 - 15:35
  • Evening Refreshments and Poster Presentations - One-to-One Networking Meetings 16:05 - 16:55
  • Agonist checkpoint combination studies 16:55 - 17:25
  • Biomarkers for prognosis and prediction to immunotherapies 17:25 - 17:55
  • Closing remarks from the Chairman 17:55 - 18:00

Day 2

Stream A: Monoclonal and Bispecific Antibodies

  • New Antibodies Development and Tumor Microenvironment
  • Keynote: Anti PD-! Antibodies are Transforming Cancer Care both as Mono- and Combination Therapy 09:05 - 09:35
    • Roy Baynes, Senior Vice President, Merck
  • Combinations of antibodies and small molecules in the Immuno-Oncology world: A TG Therapeutics perspective 09:35 - 10:05
    • Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics
  • Targeting Immunosuppressive Sialoglycans in the Tumor Microenvironment Using A Novel Therapeutic Modality EAGLE 10:05 - 10:35
    • Li Peng, Senior Vice President, Palleon Pharma
  • Morning Refreshments and Poster Presentations - One-to-One Networking Meetings 10:35 - 11:25
  • Novel T cell engaging bispecific antibodies for cancer immunotherapy 11:25 - 11:55
    • Thomas Tan, Vice President, Immunology, Elstar Therapeutics
  • B7-H3, an attractive target of antibody-based immunotherapy 11:55 - 12:25
    • Soldano Ferrone, Professor of Surgery, Massachusetts General Hospital, Harvard Medical School
  • Role of Immune Activation Profiling in clinical trials 12:25 - 12:55
  • Lunch and Poster Presentations - One-to-One Networking Meetings 12:55 - 13:55
  • Study of cytotoxic payloads-in vivo assays and efficacy testing 13:55 - 14:25
  • Predicting the toxicity of Immuno-Oncology studies 14:55 - 15:25
  • Closing remarks from the Chairman 15:25 - 15:30
  • End of Conference 15:30 - 15:45

Stream B: Immune Checkpoint Inhibitors & Combination Strategies

  • Personalized Immunotherapy and T-Cell Therapies
  • Keynote: Improving efficacy of CPI's by selected combination therapy 09:05 - 09:35
    • Carl Morrison, President, Chief Medical Officer, OmniSeq
  • Development of effective immunotherapeutic combinations with antitumor activities 09:35 - 10:05
    • Joost Oppenheim, Head, Cellular Immunology, NIH
  • Update on ICI data in early and metastatic breast cancer 10:05 - 11:25
    • Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene
  • Comparing immunological marker signatures across various cancer types 11:25 - 11:55
    • Natalie Russi, Scientific Project Manager, Nebion
  • Systematic Approaches to Identifying and Overcoming Resistance to Immune Checkpoint Inhibitors 11:55 - 12:25
  • Oncolytic viruses in the era of Checkpoint Blockade 12:25 - 13:55
  • Lunch and Poster Presentations - One-to-One Networking Meetings 12:55 - 13:55
  • Role of Nanotechnology with a combinatorial approach for solid tumors 13:55 - 14:25
  • Future opportunities in clinical development of ICI combinations 14:55 - 15:25
  • Closing remarks from the Chairman 15:25 - 15:30

For more information about this conference visit https://www.researchandmarkets.com/r/fdb1pe

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900